Ultimovacs has announced the results of the NIPU clinical trial, which evaluated the effectiveness of its cancer vaccine UV1 in combination with checkpoint inhibitors ipilimumab and nivolumab in the second-line treatment of malignant mesothelioma. The trial demonstrated a significant improvement in overall survival compared to ipilimumab and nivolumab alone, with no additional safety concerns. The results support further development of UV1 as a treatment option for mesothelioma patients. Ultimovacs will share the full dataset at the ESMO Congress and is optimistic about the potential of UV1 in other ongoing Phase II trials.
https://ultimovacs.com/investors/news/ultimovacs-announces-nipu-results-presented-at-esmo-2023-significant-and-clinically-meaningful-improvement-in-overall-survival-for-patients-receiving-uv1-cancer-vaccine-in-phase-ii-nipu-trial-in-mali